AstraZeneca Sues Zydus to Block Copies of Tagrisso Cancer Drug

AstraZeneca said Zydus amended its application for FDA approval of its proposed generic version of Tagrisso to include a new use, infringing a patent for the blockbuster cancer drug.

• Astra is seeking a court order blocking copies until patent has expired, according to complaint filed Friday in federal court in Wilmington, Delaware
• Patent covers pharmaceutical compositions comprising osimertinib mesylate, Tagrisso’s active ingredient, and methods of using them, and expires in January 2035, complaint says
• Astra in February 2020 sued Zydus, Alembic and MSN Labs over the same patent
  • Zydus told Astra in March 3 letter it had amended its application ...